|
已读[18]
发布： 2013/06/08 06:40:53
USPRwire (press release) Its products include 5-Fluorouacil, dotacexel, paclitaxel, cyclophosphamide, irinotecan , busulfan, lenalidomide, doxorubicin, thalidomide, imatinib myselate, tyrosine kinase inhib, gemicitabine, risperidone, vincristine and clozapine. The company ... and more »
|
|
|
|
|
已读[18]
发布： 2013/06/08 06:39:54
Wall Street Journal Additionally, the poster presentation entitled "Phase II clinical activity and tolerability of the SMAC-mimetic birinapant (TL32711) plus irinotecan in irinotecan -relapsed/refractory metastatic colorectal cancer" (Abstract 3621) reported clinical ...
|
|
|
|
|
已读[19]
发布： 2013/06/08 06:39:16
The Oncology Report CHICAGO – The combination of bevacizumab and irinotecan far outshone tenozolomide in delaying disease progression among patients with MGMT-unmethylated glioblastoma, an investigator reported at the annual meeting of the American Society of ...
|
|
|
|
|
已读[460]
发布： 2013/06/07 23:30:23
公司培门冬酶、碘佛醇、碘克沙醇、钠钾镁钙葡萄糖注射液、七氟皖、艾瑞昔布是独家产品,中标概率较大,预计价格不受影响;奥沙利铂(100ml:0.1g规格独家),...
|
|
|
|
|
已读[292]
发布： 2013/06/07 23:28:27
继注射剂品种伊立替康和奥沙利铂分别通过FDA和欧盟认证之后,来曲唑实现了公司首个口服制剂在FDA和欧盟的双料认证,该产品在欧盟是以互认可程序在荷兰上市,并可以在...
|
|
|
|
|
已读[258]
发布： 2013/06/07 23:26:08
风险提示 奥沙利铂基药招标降价风险,阿帕替尼、19K 等新药获批风险。益盟操盘手声明:网站所载文章、数据等内容纯属作者个人观点,仅供投资者参考,并不构成投资建议...
|
|
|
|
|
已读[266]
发布： 2013/06/07 23:25:29
我们预计:①抗肿瘤药:受国家发改委降价影响,预计肿瘤线产品略有增长,其中新品替吉奥有望翻倍,伊立替康逐步替代奥沙利铂,奥沙利铂受基药影响可能略有下滑;②...
|
|
|
|
|
已读[264]
发布： 2013/06/07 23:23:47
我们预计①抗肿瘤药:受国家发改委降价影响,预计肿瘤线产品略有增长,其中新品替吉奥有望翻倍,伊立替康逐步替代奥沙利铂,奥沙利铂受基药影响可能略有下滑。②...
|
|
|
|
|
已读[275]
发布： 2013/06/07 23:23:13
FDA)通知,公司生产的来曲唑片通过美国FDA认证,获准在美国市场销售,这是公司第三个通过规范市场认证的制剂产品,此前公司伊立替康注射液通过FDA认证、注射用奥沙利铂...
|
|
|
|
|
已读[19]
发布： 2013/06/07 04:23:50
The Oncology Report CHICAGO – The combination of bevacizumab and irinotecan far outshone tenozolomide in delaying disease progression among patients with MGMT-unmethylated glioblastoma, an investigator reported at the annual meeting of the American Society of ...
|
|
|
« 上一页 |
查看结果91-100共248
|
下一页 »
|
|
